The data from the canine clinical trial are consistent with our previous studies [10,17], which provided compelling evidence that the presence of the immune checkpoint protein, CD200, in tumor lysates suppressed the ability of local APCs to activate and recruit T-cells to trigger an effective anti-tumor immune response. The gene discussed is CD200; the disease is neoplasm.